Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, is pleased to announce that at its Annual General Meeting held earlier today all resolutions were duly passed.

Contacts:

Oxford Pharmascience Group Plc
Marcelo Bravo, Chief Executive Officer +44 207 554 5875
N+1 Singer
Aubrey Powell/Lauren Kettle +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (over the counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

Oxford Pharmascience Group plc published this content on 19 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 June 2017 11:05:12 UTC.

Original documenthttp://www.oxfordpharmascience.com/content/news/archive/2017/190617.asp

Public permalinkhttp://www.publicnow.com/view/EB57800E32956D6CB204C12A0A7AC2ADA7DB2DA7